ALIQOPA

Peak

copanlisib dihydrochloride

Bayer
NDAINTRAVENOUSPOWDERPriority Review
Approved
Sep 2017
Lifecycle
Peak
Competitive Pressure
0/100

Loss of Exclusivity

LOE Date
Mar 29, 2032
73 months away
Patent Expiry
Mar 29, 2032

Patent Records (3)

Patent #ExpiryTypeUse Code
RE46856
Oct 22, 2029
SubstanceProduct
U-2124
10383876
Mar 29, 2032
SubstanceProduct
—
9636344
Mar 29, 2032
U-2124
Company
Bayer
Bayer
LEVERKUSEN, Germany
4 open jobs
External Resources
FDA Drugs@FDA
FDA approval history